The KDM5D Knockout CAL-27 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population designed to ablate KDM5D function in the human oral squamous cell carcinoma line CAL-27. This loss-of-function model comprises a heterogeneous mixture of edited cells, minimizing clonal artifacts and reflecting population-level genetic effects. The polyclonal format is particularly advantageous for studying gene function in cancer, where tumor heterogeneity is a key factor.
CAL-27 is a well-characterized cell line derived from a tongue squamous cell carcinoma, exhibiting an adherent epithelial morphology and maintaining key oncogenic properties such as rapid proliferation and invasive capacity. It is widely used in head and neck cancer research to investigate tumor biology, drug responses, and metastatic mechanisms. The cell line??s human origin and its relevance to oral cancers make it an ideal host for targeted gene disruption experiments.
KDM5D is a histone H3K4 demethylase that catalytically removes activating methyl marks (me3/me2), leading to transcriptional silencing. It is a downstream effector of androgen receptor signaling, activated by testosterone-bound androgen receptor, and it physically interacts with histone deacetylases and retinoblastoma protein to coordinate gene repression. Among its targets, KDM5D regulates protamine genes in spermatogenesis and modulates cyclin D1 and p21 expression in somatic cells. The signaling cascade includes upstream SRY and SOX9, integrating Y-chromosome-specific transcriptional regulation with broader chromatin remodeling.
In CAL-27 cells, KDM5D knockout is expected to de-repress genes normally silenced by H3K4 demethylation, potentially affecting tumor suppressor pathways, cell cycle control, and androgen responsiveness. This model provides a tool to explore how loss of a Y-linked epigenetic regulator influences oral cancer progression, given that androgen receptor activity has been implicated in head and neck tumorigenesis. Furthermore, it allows investigation of epigenetic mechanisms shared between cancer and developmental disorders such as intellectual disability and spermatogenic failure, leveraging the cell line??s facile manipulation.
Researchers can employ this knockout model in chromatin immunoprecipitation followed by qPCR or sequencing to map genome-wide H3K4me3 changes, RNA-seq for transcriptomic profiling, and RT-qPCR for validating downstream effectors. Functional assays include flow cytometry for cell cycle analysis, migration/invasion assays, and drug sensitivity testing with antiandrogens or epigenetic modifiers. Immunofluorescence and Western blotting confirm KDM5D loss and histone mark alterations, while luciferase reporters measure androgen signaling activity. For further details or to inquire about this product, please contact Ascent Research.
